.Nature Medicine, Published online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Perspective calls for inclusion of patients along with MASLD and size of liver outcomes in cardio-- kidney-- metabolic trials, when data advise mechanistically tenable benefits and also professional safety and security-- and describes considerations for test layout and also governing approval.